Chinese API producers shielded from medium-term pain despite COVID-19-related market rebalancing: Fitch Ratings
Reducing dependence on China would increase production costs for generic drug makers, analysts say
Chinese active pharmaceutical ingredient manufacturers are unlikely to suffer any medium-term effects from increasing trade protectionism and buyers’ moves to diversify their supply amid the COVID-19 pandemic, but those with high exposure to India could lose business due to the country’s initiatives to reduce reliance on Chinese production, according to analysts at Fitch Ratings.
In the report ‘No Near-Term Impact on Chinese API Makers as Pharma Supply-Chain Shifts,’ the company said China's API production has recovered earlier than global peers' as business activities are returning to normal following the lifting of quarantines to stop the spread of COVID-19.
“Hence, it is better positioned to capture the increased drug demand generated by the outbreak, as well as demand redirected from overseas markets that have halted production,” Fitch said.
Major Chinese API manufacturers have reported strong sales in Q1, with Shenzhen Hepalink Pharmaceutical Group and Zhejiang Huahai Pharmaceutical seeing their respective revenue increase by 37.1% and 31% year-on-year, versus growth of 6.7% and decline of 3.2% in Q1 2019.
Fitch said supply-chain disruptions caused by the coronavirus have led to China’s two largest export markets for APIs taking measures to reduce their exposure.
The US is calling for pharmaceutical companies to reduce purchases of APIs from China and move API production back on a domestic footing amid drug supply shortages, while India - the world's largest generic drug producer - has announced a USD1.3 billion investment in domestic API production to reduce its Chinese imports, which account for nearly 70% of India's API demand.
“We do not believe this rebalancing will result in a significant change in China's role in the global drug supply chain in the medium term,” Fitch said. “Sourcing less from China would increase production costs, especially for generic drug makers, for whom APIs are a significant portion of costs. In addition, China's dominance in APIs means substitutes are probably not available in the near term. China is the major supplier of raw materials for certain drugs, such as antibiotics and vitamins.”
The report added that India's recently announced domestic API production enhancement plan – which involves the establishment of drug-manufacturing industrial parks to support the output of 53 key APIs -- might take years for production to ramp up.
“There are still uncertainties over India's API production ramp-up as this will depend on price competitiveness of local production once further clarity on the government incentives emerges. As such, the impact is unlikely to be seen in the near term,” the report said.
The Fitch analysts said they believed Chinese API makers with high drug quality and diversified product portfolios that include speciality APIs are better positioned to cope with the long-term challenges arising from the coronavirus-led supply-chain rebalancing.
“The trend will also prompt Chinese API makers to increase R&D spending and improve manufacturing technology to maintain their competitiveness against rivals,” they concluded.
India and the US accounted for 16.8% and 12.5% of China's total API export value, respectively, in 2019.
Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance